Hyderabad: India's first indigenous corona vaccine kovacin has been granted emergency approval before phase-3 trials are completed in India. For this reason, there are many doubts in the minds of scientists about it. In such a situation, there was good news for covaxin. A study published in the British Medical Journal, The Lancet Infectious Disease, stated that India biotech cocaine is safe for immune-boosting vaccine. The study published in Lancet arouses confidence in this.

The study, published in The Lancet Infectious Diseases Journal, stated that volunteers who participated in the vaccine's Phase 1 trials had no serious side effects, which is coded BBV-152. The authors in the study said that all side effects were in a mild category. The adverse incident occurred and the volunteer died, but it had nothing to do with the vaccine.

Covaxin was manufactured by Hyderabad-based Bharat Biotech Company. During this time, 25,800 volunteers across the country are running phase-3. For this reason, it has been approved in clinical trial mode.

Trials were conducted between July 13 and 30 in 11 hospitals in India. During this time, 827 volunteers between the ages of 18 and 55 were tested. 375 of them were enrolled. Three groups were formed with 100-100 volunteers and 75 were placed in the control group. Both injections were conducted at a distance of 14 days.

Severe side effects have not been observed. Common side effects like fever, injection site pain, fatigue, headache are definitely visible.

Also read:

These stars will join Hindi remake of 'Krack', Director Gopichand Malini reveals

Delhi: 34 people arrested for running fake call centre

Digital Golgappa picks the top Indian books that you must read in February 2021